Navigation Links
Breast Cancer Drug May Also Help Lung Cancer Patients
Date:1/24/2011

By Amanda Gardner
HealthDay Reporter

MONDAY, Jan. 24 (HealthDay News) -- The anti-estrogen drug that transformed the treatment of breast cancer three decades ago may also reduce the risk of dying from lung cancer, researchers say.

In a study published in the Jan. 24 online edition of the journal Cancer, tamoxifen lowered the risk of dying from lung cancer among women who already had breast cancer. However, the results are too preliminary to warrant giving tamoxifen to lung cancer patients.

"There aren't a whole lot of clinical implications, but it does provide more evidence to our accumulating knowledge that female sex hormones are involved in some way, shape or form in lung cancer progression," said Dr. Apar Kishor Ganti, assistant professor of oncology-hematology at the University of Nebraska Medical Center in Omaha. "Whether or not it's a cause is a little sketchy."

Ganti was not involved with the study.

Prior studies had indicated that taking hormone replacement therapy during menopause upped a woman's chances of dying from lung cancer.

So these researchers hypothesized that the opposite might be true -- that anti-estrogens might lower a woman's risk of death from lung cancer.

Previous studies have also indicated that lung cancers, like breast and gynecological cancers, express hormone receptors.

In the current study, Dr. Elisabetta Rapiti, from the Geneva Cancer Registry, and colleagues reviewed records of 6,655 women diagnosed with breast cancer in Switzerland between 1980 and 2003. Just under half (46 percent) received anti-estrogen therapy which, during that time period, was most likely tamoxifen (aromatase inhibitors were not yet in use in Switzerland, the authors stated).

Women taking anti-estrogen therapy had an 87 percent decreased risk of death from lung cancer, compared to women who weren't taking this type of therapy.

There was no link between anti-estrogen therapy and whether or not a woman actually developed lung cancer.

One limitation to the research, Ganti noted, is that only 40 women actually developed lung cancer, so it was a very small study group.

The estrogen receptors implicated in lung cancer "don't seem to discriminate between men and women," Ganti said, indicating that anti-estrogens might have the same effect in men, although it's too early to state this definitively.

Other than breast and gynecological cancers, such as ovarian cancers, lung cancer has been the most extensively studied with regard to its interplay with estrogen, said Jing Peng, a post-doctoral associate in the Cancer Prevention Program at Fox Chase Cancer Center in Philadelphia.

There is limited evidence that estrogen may play a role in head-and-neck cancers as well.

But the issue is a complicated one, with some studies in mice suggesting that tamoxifen might actually promote lung cancer, Peng said.

"This article at least verifies that further studies should be carried out," she said.

More information

The U.S. National Cancer Institute has more on lung cancer.

SOURCES: Apar Kishor Ganti, M.D., assistant professor, oncology-hematology, University of Nebraska Medical Center, Omaha, Neb.; Jing Peng, Ph.D., post-doctoral associate, Cancer Prevention Program, Fox Chase Cancer Center, Philadelphia; Jan. 24, 2011, Cancer, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Breast Cancer Patients With Diabetes May Fare Worse
2. Strong social ties benefit breast cancer patients
3. Breastfeeding -- added protection for cancer survivors?
4. Small Spreads of Breast Cancer May Not Affect Survival
5. U-M researchers find indirect path to attack breast cancer stem cells
6. Scientists identify avoidable breast cancer risk factors
7. Breast Cancer Radiation Before 1984 Tied to Heart Disease
8. Study Finds Racial Disparity in Breast Cancer Outcomes
9. Study provides molecular rationale for combining targeted agents to treat breast cancer
10. Preoperative breast MRI suggests high cancer yield
11. Quality of life measures in breast cancer clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Drug May Also Help  Lung Cancer Patients
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall ... modular industry or whose acts have had a significant impact on the careers of all ... and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... DIEGO and VANCOUVER, British Columbia ... (NASDAQ: SPHS ) (the "Company" or "Sophiris"), ... the treatment of urological diseases, today announced that data ... evaluated the drug as a focal treatment for localized ... March 26, 2017 at the 32 nd Annual ...
(Date:3/23/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: ... company that provides clinically useful molecular diagnostic tests ... entered into agreements to successfully restructure its secured ... concurrently terminate its royalty and milestone obligations. ... RedPath amounting to $9.34 million is being acquired ...
Breaking Medicine Technology: